<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15062">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00219349</url>
  </required_header>
  <id_info>
    <org_study_id>#4941</org_study_id>
    <nct_id>NCT00219349</nct_id>
  </id_info>
  <brief_title>Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)</brief_title>
  <official_title>Cognitive-Behavioral Therapy and Pharmacotherapy Augmentation for Generalized Anxiety Disorder: A Pilot Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goals of this pilot study are as follows:

      1) To disseminate and examine the effectiveness of a manualized, individual,
      cognitive-behavioral psychotherapy (CBT) for adults with Generalized Anxiety Disorder(GAD),
      2) to test the effectiveness of augmentation (the addition of) antidepressant therapy in
      participants who do not fully respond to CBT, and 3) to examine individual and clinical
      predictors of non-response to CBT and predictors of response to augmentation antidepressant
      therapy. A related goal is to examine the maintenance of treatment gains obtained from CBT
      alone and CBT with augmentation antidepressant therapy, over a twenty-four month follow-up
      period. This study will serve as a pilot investigation in preparation for a larger federally
      funded study using this treatment approach. We hypothesize that CBT will result in remission
      (no longer having GAD) and/or high endstate functioning (clinically meaningful improvement)
      in approximately 40-50% of participants. Further, we hypothesize that augmentation
      antidepressant therapy in participants who do not fully respond to CBT will result in
      further clinically significant improvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot investigation will examine the effectiveness of augmenting cognitive behavioral
      therapy (CBT) with antidepressant pharmacotherapy (escitalopram[Lexapro]) in adults with
      generalized anxiety disorder (GAD) who do not fully respond to a temporally primary trial of
      CBT. A secondary aim of this study is to assess the maintenance of treatment gains made by
      patients in response to CBT, and to CBT with antidepressant augmentation therapy, over a
      two-year follow-up period.

      CBT is an empirically supported psychotherapy that has been found to be effective in
      treating GAD in approximately 50 percent of patients enrolled in controlled clinical trials.
      However, a substantial proportion (nearly half) of individuals with GAD do not achieve full
      remission or clinically significant improvement at the cessation of CBT. Escitalopram
      (Lexapro)is a selective serotonin reuptake inhibitor (SSRI) antidepressant, which has been
      shown to be effective in treating GAD in several large-scale controlled clinical trials. The
      Food and Drug Administration has approved ecitalopram for the treatment of GAD.

      The proposed research plan encompasses the conduct of an open clinical trial (No randomized
      placebo control) of 14 sessions of manualized individual CBT for persons meeting DSM-IV-TR
      diagnostic criteria for GAD. This study will use a treatment manual developed by Dr. Thomas
      Borkovec and colleagues at the Pennsylvania State University. Participants who meet high
      endstate functioning criteria and/or achieve remission following CBT will be evaluated
      periodically during a twenty-four month follow-up phase. Participants who do not meet high
      endstate functioning criteria and/or achieve remission following completion of CBT will be
      offered entry into a twelve-week, open-label, flexible-dose trial of escitalopram therapy.
      Participants receiving escitalopram therapy will be evaluated periodically during a
      twenty-four month follow-up phase, as well. It is anticipated that patients who do not fully
      respond to CBT will show a significant increment in improvement in GAD symptoms, over and
      above their CBT posttreatment level, following pharmacotherapy with escitalopram.

      At present, no studies with GAD populations have examined the additive or sequenced effects
      of psychosocial therapy and SSRI antidepressant pharmacotherapy. The proposed research is a
      first step in this direction and may provide evidence supporting the use of combined
      treatment modalities in CBT partial and non-responders.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Hamilton Anxiety Rating Scale Score</measure>
    <time_frame>week 14 to week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Hamilton Anxiety Rating Scale is a clinician administered rating scale assessing severity of anxiety from 0 (low) to 64 (high). The greater the magnitude of decrease in score during treatment, the greater the improvement in anxiety.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impressions-Improvement Index</measure>
    <time_frame>week 26</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impressions-Severity Index</measure>
    <time_frame>week 14 to week 26</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>GAD Severity Scale</measure>
    <time_frame>week 14 to week 26</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Penn State Worry Questionnaire</measure>
    <time_frame>week 14 to week 26</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>State-Trait Anxiety Inventory</measure>
    <time_frame>week 14 to week 26</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hamilton Anxiety Scale Score</measure>
    <time_frame>week 14 to week 26</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Rating Scale for Depression</measure>
    <time_frame>week 14 to week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory-II</measure>
    <time_frame>week 14 to week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral-Therapy</intervention_name>
    <description>14 weekly sessions of individualized CBT</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>10-20 mg per day for 12 weeks</description>
    <other_name>lexapro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females between the ages of 18 and 65 (inclusive)

          2. Primary DSM-IV-TR diagnosis of Generalized Anxiety Disorder (GAD) with no significant
             co-morbid anxiety disorder for which CBT for GAD is not appropriate including PTSD,
             OCD, and prominent panic disorder with or without agoraphobia

          3. A negative urine toxicology, i.e., a urine specimen that does not test positive for
             use of drugs of abuse, or use of benzodiazepines, in the previous three weeks

          4. Penn State Worry Questionnaire score of 55 or greater

          5. Have a score of equal to or &gt; 4 (Moderately Ill) on Clinical Global Impression (CGI)
             Scale (severity of illness item) for GAD

          6. Ability to give informed consent

          7. Fluent in English

          8. Willingness to have Cognitive-Behavioral Therapy sessions audiotaped -

        Exclusion Criteria:

          1. Patients who have a diagnosis of Major Depressive Disorder within 60 days prior to
             the clinical interview, and patients who have a &quot;lifetime&quot; history of being diagnosed
             with one or more of the following disorders: Schizophrenia, Major Depressive Disorder
             with Psychotic or Catatonic features, Bipolar I Affective Disorder, or Organic Mental
             Disease

          2. DSM-IV substance abuse or dependence within the past 6 months (except nicotine or
             caffeine)

          3. Active suicidal or homicidal ideation, or judged to be at serious suicide risk

          4. Hamilton Rating Scale for Depression score of greater than 20 at Screening or
             Baseline evaluation

          5. Any unstable medical or neurological condition

          6. Women who are pregnant or lactating

          7. Having received CBT treatment for GAD previously

          8. Concurrent psychosocial therapy

          9. Current psychotropic medication with exception of zolpidem at hs for insomnia

         10. History of nonresponse to an adequate trial of escitalopram or intolerable adverse
             effects to escitalopram -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franklin R. Schneier, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth D Belzer, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anxiety Disorders Clinic, New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nyspi.org</url>
    <description>New York State Psychiatric Institute Homepage</description>
  </link>
  <link>
    <url>http://www.adaa.org</url>
    <description>Anxiety Disorders Association of America Homepage</description>
  </link>
  <results_reference>
    <citation>Schneier FR, Belzer KD, Kishon R, Amsel L, Simpson HB. Escitalopram for persistent symptoms of generalized anxiety disorder after CBT: a pilot study. J Nerv Ment Dis. 2010 Jun;198(6):458-61. doi: 10.1097/NMD.0b013e3181da4d77.</citation>
    <PMID>20531128</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 11, 2012</lastchanged_date>
  <firstreceived_date>September 14, 2005</firstreceived_date>
  <firstreceived_results_date>February 29, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anxiety Disorders</keyword>
  <keyword>Anxiety Neuroses</keyword>
  <keyword>Behavior Therapy, Cognitive</keyword>
  <keyword>Escitalopram</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cognitive-behavioral Therapy</title>
          <description>14 weekly sessions of individual cognitive-behavioral therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cognitive Behavioral Therapy Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Escitalopram Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15">7 responders to CBT were ineligible to start and 1 declined, leaving 7 who started escitalopram</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cognitive-behavioral Therapy</title>
          <description>14 weekly sessions of individual cognitive-behavioral therapy</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="41" spread="11.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hamilton Anxiety Rating Scale Score</title>
        <description>The Hamilton Anxiety Rating Scale is a clinician administered rating scale assessing severity of anxiety from 0 (low) to 64 (high). The greater the magnitude of decrease in score during treatment, the greater the improvement in anxiety.</description>
        <time_frame>week 14 to week 26</time_frame>
        <safety_issue>No</safety_issue>
        <population>see above: Patients who completed the CBT phase and started escitalopram treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Who Started Escitalopram</title>
            <description>Patients who completed the CBT phase and started escitalopram phase treatment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Hamilton Anxiety Rating Scale Score</title>
            <description>The Hamilton Anxiety Rating Scale is a clinician administered rating scale assessing severity of anxiety from 0 (low) to 64 (high). The greater the magnitude of decrease in score during treatment, the greater the improvement in anxiety.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-6.4" spread="10.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Global Impressions-Improvement Index</title>
        <time_frame>week 26</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Global Impressions-Severity Index</title>
        <time_frame>week 14 to week 26</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GAD Severity Scale</title>
        <time_frame>week 14 to week 26</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Penn State Worry Questionnaire</title>
        <time_frame>week 14 to week 26</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>State-Trait Anxiety Inventory</title>
        <time_frame>week 14 to week 26</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Hamilton Anxiety Scale Score</title>
        <time_frame>week 14 to week 26</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Rating Scale for Depression</title>
        <time_frame>week 14 to week 26</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory-II</title>
        <time_frame>week 14 to week 26</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>all subject entered</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Franklin Schneier MD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>2125435368</phone>
      <email>fschneier@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
